Effect of Extra- Fine Versus Coarse-Particle Inhaled Corticosteroids (ICS) on Ventilation Heterogeneity in Children With Poorly Controlled Asthma



Status:Completed
Conditions:Asthma
Therapuetic Areas:Pulmonary / Respiratory Diseases
Healthy:No
Age Range:6 - 17
Updated:10/27/2018
Start Date:June 2016
End Date:July 6, 2018

Use our guide to learn which trials are right for you!

The primary objective of the study is to show that ventilation heterogeneity identified by
hyperpolarized helium-3 lung MRI is prevalent children with poorly controlled asthma despite
guidelines-based treatment with ICS. The secondary objective is to demonstrate whether or not
eight weeks of treatment with extra-fine particle ICS (HFA-BDP) improves ventilation
heterogeneity compared to treatment with a coarse particle ICS (fluticasone HFA or dry
powder).


Inclusion Criteria:

- Boys and girls between the ages of 6 and 17 years

- Diagnosis of asthma based on NAEPP3 criteria

- Poor asthma control based on one or more of the following criteria:

an ACT ≤ 19 and/or ACQ ≥ 1.5 units at the screening and/or randomization visits despite
continuous or intermittent treatment with ICS and/or an anti-leukotriene within six months
before enrollment.

- Any airflow obstruction based on Hankinson et al reference standards: FEV1 % < 80%
predicted, an FEV1/FVC ratio < 90% predicted, and/or an FEF 25-75 < 70% predicted at
the screening and/or randomization visits.

- Frequent severe exacerbations as reflected by ≥ 2 bursts of systemic corticosteroids
(≥ 3 days each) in the previous 12 months.

- Serious exacerbations reflected by at least one hospitalization, ICU stay, or
mechanical ventilation in the previous 12 months

- "Not well controlled" by NAEPP or GINA asthma treatment guidelines

- For post-pubertal females, negative urine pregnancy screen and willing if sexually
active (as counseled by a female study coordinator in private) to using a consistent
and appropriate method of birth control for the duration of the study.

Exclusion Criteria:

- Premature birth < 35 weeks estimated gestational age

- Maintenance oral prednisone (defined as daily or alternate day for the past three
months before screening) or omalizumab treatment for asthma control

- Any significant medical condition that might inform maldistribution of ventilation
apart from asthma including bronchiectasis, cardiac disease, congenital anomalies of
the respiratory system, neurodevelopmental delay with cognitive impairment, ciliary
dyskinesia syndromes, immune deficiency, recent lower respiratory infection (within
six weeks of screen visit). Co-morbidities associated with asthma including sleep
apnea syndrome, obesity, GERD, and right middle lobe syndrome are not criteria for
exclusion.

- Claustrophobia, inner ear implants, aneurysm or other surgical clips, metal foreign
bodies in the eye, pacemaker, or other contraindication to MR scanning. Subjects with
any implanted device that cannot be verified as MRI compliant will be excluded.

- Chest circumference greater than that of the helium coil. The circumference of the
coil is approximately 42 inches.

- Inability to understand simple instructions or to hold still for 10 seconds.
We found this trial at
1
site
Charlottesville, Virginia 22908
Phone: 434-982-4206
?
mi
from
Charlottesville, VA
Click here to add this to my saved trials